SECURITIES
PURCHASE AGREEMENT ZANDER THERAPEUTICS, INC.


 


THIS
SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the "Company") whose address is 4700 Spring Street, St 304, La Mesa, California 91942, and ______________ ("Purchaser
'), a trust whose address is________________________.


 


The
Securities offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Act")
and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant
to an exemption from, or in a transaction not subject to, the registration requirement of the Act. The Securities are being offered
and sold only to "accredited investors" (as defined in Rule 501 of Regulation D under the Securities Act).


 


WHEREAS:


 


The
Purchaser desires to purchase shares of the common stock of the Company ("Shares") in accordance with the terms and
conditions set forth herein.


 


The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.


 


THEREFORE,
IT IS AGREED AS FOLLOWS


 


 1. Purchase Price




 


The
purchase price per Share ('"Purchase Price"), payable in US Dollars, shall be $2.00 per Share.


 


 2. Form of Payment




 


The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company.


WIRE
INSTRUCTIONS:


 



    	 	1	 



     


    

 


Issuance
of Stock


 


10
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased


 


3.
Purchaser's Representations and Warranties


 





	(a)		As of the
date hereof, the Purchaser is purchasing the Shares for its own account and not with a present view towards the public sale or
distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended
(the "Act").



	(b)		The Purchaser
is an '"accredited investor" as that term is defined in Rule 501(a) of Regulation D promulgated under the Act.





	(c)		The Purchaser
and its advisors if any, have been, furnished with all materials relating to the business, finances and operations of the Company
and materials relating to the offer and sale of the Stocks which have been requested by the Purchaser or its advisors. Notwithstanding
the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information
unless such information is disclosed to the public prior to such disclosure to the Purchaser.



	(d)		Purchaser
has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval
or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.





	(e)		The execution,
delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser's breach of any statute or
regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any
of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the
Purchaser is a party, or by which Purchaser is or may be bound.



4.
Company's representations and warranties




 


	(a)		Company
is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has the
requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent, approval
ora uthorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.



	(b)		The execution,
delivery and performance of this Agreement by Company does not and shall not constitute Company's breach of any statute or regulation
or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms,
conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a
party, or by which Company is or may be bound.



 5. Restricted Securities Acknowledgement




 


SHARES
TO BE ISSUED PURSUANT TO THIS AGREEMENT WILL NOT BE REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE
SECURITIES ACT OF 1933 OR THE SECURITIES LAW OF ANY STATE OR OTHER JURISDICTION.


 


Purchaser
acknowledges that any securities issued pursuant to this Agreement shall not be registered pursuant to the Securities Act of 1933
and shall constitute "restricted securities" as that term is defined in Rule 144 promulgated under the Act, and shall
contain the following restrictive legend:


 


"THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ''ACT"), OR SECURITIES LAWS OF ANY
STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS."


 


 9. Entire Agreement




 


This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.


 


 10. Governing Law, Venue, Waiver Of Jury Trial




 


All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and
construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of
conflicts of law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in California for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is improper or inconvenient venue for such proceeding. If either party
shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action
or proceeding shall be reimbursed by the other party for its attorneys' fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.


 





IN
WITNESS WHEREOF, the parties have hereunto executed
this Agreement on the 15th day of June, 2018.


 





	Zander Therapeutics, Inc	 	 
	 	 	 
	/s/ David Koos	 	 
	David Koos, CEO	 	 
	 	 	 
	June 16, 2018	 	 
	 	 	 
	 	 	 
	Purchaser	 	 
	 	 	 
		 	 
	June 15, 2018	 	 
	 	 	 



 


Number
of shares of common Stock Purchased: 50,000 shares @$2:00 per Share